Skip to content

Amlogenyx

1 viewer · 30d

Total raised

$10.0M

+$10.0M this year

1 filing since 2026 · latest Other filed

Cumulative raised
LAST ROUND
Other · $10.0M
ROUNDS
1
INVESTORS
2
FOUNDED
2023
HQ
Novato, CA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Amlogenyx is a Novato, California biotechnology company developing gene therapies that reduce amyloid accumulation in the brain in order to prevent and treat Alzheimer's disease and other amyloid diseases. It was spun out of Ultragenyx Pharmaceutical (NASDAQ: RARE), which retains majority ownership, and closed a $14M seed round backed by Ultragenyx and GordonMD Global Investments. Its lead candidate AM805 is an investigational AAV9 gene therapy that delivers protective protein/cathepsin A (PPCA), a lysosomal enzyme that degrades amyloid-beta. The company reported positive preclinical data in March and May 2026, plans to submit an IND later in 2026, and anticipates Phase 1/2 studies in 2027.

What sets it apart

Instead of clearing amyloid with monoclonal antibodies, AM805 uses a catalytic enzyme delivered once by gene therapy. PPCA secreted by transduced cells is taken up by neighbouring cells — a cross-correcting mechanism that degrades both intracellular and extracellular amyloid-beta, with preclinical amyloid reductions the company reports as comparable to or exceeding approved Alzheimer's antibodies.

Funding history

1 round
OtherJul 1, 2026
Form D
+$10.0M$10.0M total

Latest SEC filings

via EDGAR · CIK 0002031988
Form D · Jul 1, 2026NewView on EDGAR

Products

1 tracked

AM805

Investigational AAV9 gene therapy

An investigational AAV9-mediated gene therapy designed as a one-time treatment for Alzheimer's disease, delivering protective protein/cathepsin A (PPCA) — a lysosomal carboxypeptidase — directly to the brain to degrade amyloid-beta (Abeta42).

  • AAV9 vector delivering the PPCA enzyme to the brain
  • Catalytic protease mechanism that cleaves amyloid-beta and prevents oligomer formation
  • Cross-correcting mechanism: PPCA secreted by transduced cells is absorbed by neighbouring cells for widespread clearance
  • Reduces both intracellular and extracellular amyloid-beta in preclinical models

Links

WebsiteLinkedInSEC EDGAR filings